Back to
Citadel Advisors LLC
VRTX
32 quarters
Position history for
Citadel Advisors LLC's holdings in Vertex Pharmaceuticals Incorporated
Yes. Citadel Advisors holds 1,032,674 shares of VRTX (Vertex Pharmaceuticals), worth $539.9M, as of its Q3 2026 13F filing. It increased the position by 522,244 shares (+102.3%) from Q2 2026. Citadel Advisors has held VRTX since Q3 2022, across 17 quarterly 13F filings. VRTX is 0.1% of Citadel Advisors' reported 13F portfolio.
Current Value
$539.9M
Current Shares
1M
Total Value Change
+$393.5M
Total Shares Change
+149,151
Quarter-by-Quarter History
Other major holders of VRTX: Capital World Investors